Skip to main content
. Author manuscript; available in PMC: 2017 Nov 6.
Published in final edited form as: Biochem Pharmacol. 2016 Jun 14;113:88–96. doi: 10.1016/j.bcp.2016.06.007

Fig. 3.

Fig. 3

hsa-miR-25-3p oligonucleotides interact directly with CYP2B6 mRNA oligonucleotides in an Ago4-dependent manner. (A) RNA EMSA shows that hsa-miR-25-3p interacts with CYP2B6 mRNA oligonucleotides to form an electrophoretically stable complex (Arrow, lane 6); no such an interaction was observed between hsa-miR-504-5p and CYP2B6 mRNA oligonucleotides (lane 5). (B) The interaction between hsa-miR-25-3p oligonucleotides and CYP2B6 mRNA oligonucleotides is sequence specific in the presence or absence of HepaRG protein extracts, since cold probe can reduce the density of the hsa-miR-25-3p/CYP2B6 complexes and the density of the hsa-miR-25-3p/CYP2B6/protein complex (Arrows). (C). Antibody against Ago4 was able to capture hsa-miR-25-3p/CYP2B6/protein complex (Upper arrow, supershift complex). *hsa-miR-25-3p targeting mRNA sequence in CYP2B6 3′-UTR. *hsa-miR-504-5p targeting mRNA sequence in CYP2B6 3′-UTR.